TumorDiagnostik & Therapie, Table of Contents TumorDiagnostik & Therapie 2019; 40(03): 165-170DOI: 10.1055/a-0824-9933 Schwerpunkt Pankreaskarzinom © Georg Thieme Verlag KG Stuttgart · New York Pathogenese und Diagnostik beim Pankreaskarzinom Alexander Ioannis Damanakis , Florian Gebauer , Felix Popp , Christiane Bruns Recommend Article Abstract Buy Article Trotz komplexer multimodaler Behandlungsansätze sterben ca. 90 % der Patienten am Pankreaskarzinom. In den letzten Jahren hat vor allem die bessere Aufarbeitung genetischer Alterationen das Verständnis zur Pathogenese des Pankreaskarzinoms verbessern können. Wir fassen die neuen Erkenntnisse zur Pathogenese zusammen und erläutern Methoden zur Detektion und diagnostischen Aufarbeitung. Full Text References Literatur 1 Basturk O, Hong SM, Wood LD. et al. A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Amer J Surg Pathol 2015; 39: 1730-1741 2 Ott C, Heinmöller E, Gaumann A. et al. Intraepitheliale Neoplasien (PanIN) und intraduktale papillär-muzinöse Neoplasien (IPMN) des Pankreas als Vorläufer des Pankreaskarzinoms. Med Klinik 2007; 102: 127-135 3 Vincent A, Herman J, Schulick R. et al. M. Pancreatic cancer. Lancet 2011; 378: 607-620 4 Mateos R, Conlon KC. Pancreatic cancer. Surgery 2016; 34: 282-291 5 Haugk B, Raman S. Pancreatic pathology: an update. Surgery 2016; 34: 273-281 6 Kamisawa T, Wood LD, Itoi T. et al. Pancreatic cancer. Lancet 2016; 388: 73-85 7 Jones S, Zhang X, Parsons DW. et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science 2008; 321: 1801 8 Gukovsky I, Li N, Todoric J. et al. Inflammation, Autophagy, and Obesity: Common Features in the Pathogenesis of Pancreatitis and Pancreatic Cancer. Gastroenterol 2013; 144: 1199-1209.e4 9 Ansari D, Gustafsson A, Andersson R. Update on the management of pancreatic cancer: Surgery is not enough. World J Gastroenterol 2015; 21: 3157-3165 10 Korc M. Smad4-TGF-β Signaling Pathways in Pancreatic Cancer Pathogenesis. Pancreatic Cancer 2018; Second edition: 431-455 . doi:10.1007/978-1-4939-7193-0_17 11 Tanaka S. Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer. Ann Surg Oncol 2016; 23: 197-205 12 Yamada S, Fujii T, Shimoyama Y. et al. SMAD4 Expression Predicts Local Spread and Treatment Failure in Resected Pancreatic Cancer. Pancreas 2015; 44: 660-664 13 Lennon A, Wolfgang CL, Canto MI. et al. The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia?. Cancer Res 2014; 74: 3381-3389 14 Waddell N, Pajic M, Patch AM. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518: 495-501 15 Conroy T, Desseigne F, Ychou M. et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med 2011; 364: 1817-1825 16 Suker M, Beumer BR, Sadot E. et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 2016; 17: 801-810 17 Feig C, Gopinathan A, Neesse A. et al. The Pancreas Cancer Microenvironment. Clin Cancer Res 2012; 18: 4266-4276 18 Ryan DP, Hong TS, Bardeesy N. Pancreatic Adenocarcinoma. N Engl J Med 2014; 371: 1039-1049 19 Choe JH. Emerging Therapeutic Targets in Pancreatic Adenocarcinoma. Springer 2018; 20 Perera RM, Bardeesy N. Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up. Cancer Discov 2015; 5: 1247-1261 21 Iodice S, Gandini S, Maisonneuve P. et al. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbeck’s Arch Surg 2008; 393: 535-545 22 Raimondi S, Lowenfels AB, Morselli-Labate AM. et al. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Practice & Research Clin Gastroenterol 2010; 24: 349-358 23 Bosetti C, Rosato V, Li D. et al. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. Ann Oncol 2014; 25: 2065-2072 24 Jacobs EJ, Chanock SJ, Fuchs CS. et al. Family history of cancer and risk of pancreatic cancer: A pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer 2010; 127: 1421-1428 25 AWMF. S3-Leitlinie Exokrines Pankreaskarzinom, Langversion 1.0. 2013 www.awmf.org/leitlinien/detail/ll/032-010OL.html , abgerufen am 3.2.2019 26 NCCN. NCCN Clinical Practice Guidelines in Oncology Pancreatic adenocarcinoma. 2016 www.nccn.org/professionals/physician_gls/default.aspx , abgerufen am 3.2.2019 27 Walters DM, LaPar DJ, de Lange EE. et al. Pancreas-Protocol Imaging at a High-Volume Center Leads to Improved Preoperative Staging of Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 2011; 18: 2764-2771 28 Bipat S, Phoa SS, van Delden OM. et al. Ultrasonografy, Computed Tomografy and Magnetic Resonance Imaging for Diagnosis and Determining Resectability of Pancreatic Adenocarcinoma. J Comp Assist Tomogr 2005; 29: 438-445 29 Isaji S, Mizuno S, Windsor JA. et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatol 2018; 18: 2-11 30 Chiorean E, von Hoff DD, Reni M. et al. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncology 2016; 27: 654-660
